17 research outputs found
273 Is PSA doubling time reliable as a progression risk criterion for patients with low-risk prostate cancer in an active surveillance programme?
529 ERG protein expression is not an independent risk-factor for development of castration-resistant prostate cancer in advanced and metastatic disease treated with androgen deprivation therapy
345 ERG-expression is an independent predictor of disease progression during active surveillance
Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics:a retrospective real-world evidence study
323 Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study
Active surveillance vs. radical prostatectomy in favourable-risk localised prostate cancer
Survival outcomes from a cumulative analysis of worldwide observational studies on sequential use of new agents in metastatic castration-resistant prostate cancer (vol 18, pg 69, 2020)
Experimentele farmacotherapi